在中国开发与癌症相关的静脉血栓形成风险评估工具:修改后的德尔菲分析层次过程研究
Xiaoli Qin1,2, Xiurong Gao2, Yujie Yang1
1Department of Pharmacy, The Third People's Hospital of Chengdu, 610031, Chengdu, Sichuan, P.R. China.
BMC cancer
|January 23, 2024
概括
在中国开发了一种与癌症相关的静脉血栓瘤 (VTE) 的新风险评估工具. 这种经过验证的工具有助于评估静脉瘤风险,并指导癌症患者的血栓预防干预.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 医疗信息学 医疗信息学
背景情况:
- 癌症患者面临高风险的静脉血栓栓塞 (VTE).
- 准确的风险评估对于有效的血栓预防治疗至关重要.
- 现有的工具可能没有针对中国人口进行优化.
研究的目的:
- 专门为中国开发和验证针对癌症相关静脉血栓的综合风险评估工具.
- 确定评估中国癌症患者VTE风险的关键指标.
主要方法:
- 为了达到专家的共识,使用了经过修改的两轮德尔菲方法.
- 分析层次过程 (AHP) 确定了指标的相对重要性.
- 专家反,匿名意见和知识交换为工具开发提供了信息.
主要成果:
- 专家达成高度共识 (85.19%第一轮,82.61%第二轮).
- 最终的工具包括3个域,10个子域和39个指标.
- 疾病因素 (0.4905) 的重量最高,其次是治疗因素 (0.3119) 和患者因素 (0.1976).
结论:
- 开发的风险评估工具是有效的,可靠的和权威的.
- 它可以有效地评估中国与癌症相关的VTE风险.
- 该工具支持启动适当的血栓预防干预措施.
相关概念视频
Hazard Ratio
124
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
124
Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348


